Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature
Dariusz Kata, Katarzyna Mrówka-Kata, Marek Seweryn, Jacek Pająk, Jacek Najda, Sławomira Kyrcz-Krzemień
20100801
2010 Sept 1
Leuk Res
Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature
Leuk Res. 2010 Sept;34(9), Dariusz Kata, Katarzyna Mrówka-Kata, Marek Seweryn, Jacek Pająk, Jacek Najda, Sławomira Kyrcz-Krzemień
Abstract
1IntroductionImatinib mesylate has revolutionized the treatment of chronic myeloid leukemia (CML), providing an excellent disease control and showing a satisfactory tolerance [1]. However, due to a relatively short period of about 10 years of the clinical experience with this drug, a possible contribution of imatinib to the development of secondary neoplasms has not been definitively determined. Recently, Frustaci et al. [2] reported on the occurrence of colon adenocarcinoma in 2 out of 150 CML late...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
